Skip to main content

FDA Approvals

Keytruda Now Approved for the Adjuvant Treatment of Stage IIB/IIC Melanoma

Orencia First Drug FDA Approved for the Prevention of Acute Graft-versus-Host Disease

Kimmtrak, a Bispecific CD3 T-Cell Engager, First FDA-Approved Drug for Unresectable or Metastatic Uveal Melanoma

FDA Approved Fyarro for Malignant Perivascular Epithelioid-Cell Tumor

Oral Scemblix FDA Approved for Patients with Ph-Positive Chronic Myeloid Leukemia

Verzenio with Endocrine Therapy FDA Approved for Adjuvant Treatment of Early Breast Cancer

Tecartus FDA Approved for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia

Nivolumab First Immunotherapy Approved for Adjuvant Treatment of Urothelial Carcinoma

Jemperli Another Therapy Approved for Patients with dMMR Recurrent or Advanced Solid Tumors

Page 7 of 21
Results 61 - 70 of 202